ASCO26: Sara Tolaney, MD, MPH, ASCENT-03 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

Share

  • 1

    Dr. Sara Tolaney presented data from the ASCENT-03 study at ASCO26.

  • 2

    The study focuses on advanced triple-negative breast cancer.

  • 3

    Sacituzumab govitecan is being evaluated as a first-line treatment.

  • 4

    The data supports the case for its approval.

  • 5

    The research was conducted at Dana-Farber Cancer Institute.

Original Source(s)

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

  • July 1, 2026

Related Content

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

  • September 7, 2026

  • 3 min
Toward Precision Cardio-Oncology in Breast Radiotherapy